Experts discuss combination and sequencing approaches for radiopharmaceuticals in advanced prostate cancer

Dr. Pedro Barata and Dr. Johann De Bono review the current questions surrounding how best to combine and sequence radiopharmaceutical therapies for patients with metastatic castration‑resistant prostate cancer. They highlight that while several agents are available, the optimal order and pairing of treatments remain unclear.

The discussion is part of a broader series that examines radiopharmaceutical strategies, patient selection, safety management, and future directions in this disease area. The experts stress the importance of clinical data to guide decisions and improve outcomes for patients.

Overall, the conversation underscores the need for continued research to define the most effective combination and sequencing regimens for mCRPC, with a focus on balancing efficacy and toxicity.